HIV Treatment Bulletin - Vol. 7, No. 6, June 2006
Polly Clayden, HIV i-Base

A poster from J Lam and coworkers from the University of Southern California (USC), Pharmacology, Los Angeles, USA reported their methodology for total drug analysis from plasma with protein precipitation. This methodology simultaneously analyses multiple protease inhibitors in a single run, with a smaller injection volume, making it easier to use TDM, particularly in paediatrics, than previously published assays.

The investigators added a volume of 100 μL of 500 ng/mL of SQV as the internal standard to 100 mcg/mL of each plasma standard. The entire sample was protein precipitated by adding 500 μL of acetonitrile and centrifuged at 13,000 rpm for 5 minutes. The supernatant was evaporated to dryness, reconstituted with 150 μg/mL of mobile phase (58%: [v/v] acetonitrile + 42% 20 mM NH4Acetate, pH4.5), and then centrifuged for 5 minutes at 13,000 rpm. An aliquot of 135 μg/mL of the supernatant was transferred into HPLC injection vials.

A volume of 10 μL per sample was injected and the concentration was determined using a Sciex API 3+ mass spectrometer coupled with an Agilent 1100 HPLC and well plate autosampler. The analytes were separated using a Hypurity C18 column (50 × 4.6 mm, 5 μm), where the flow-rate was 0.4 mL/min to elute the PIs.

The investigators found the CVs for both intra and inter-day precision were <10% for each compound. Accuracy was measured at >85%. Retention times were 1.44, 2.57, 4.12, 4.28, and 4.35 minutes for ritonavir, saquinavir, nelfinavir, lopinavir, and atazanavir, respectively. The total sample run time was 7.2 minutes.

The mass transitions were 705.3 to 335.3, 568.2 to 330.2, 721.2 to 296.2, 629.4 to 447.6 and 671.3 to 570.3 for atazanavir, nelfinavir, ritonavir, lopinavir, and saquinavir, respectively.

This methodology was validated over the concentration ranges of 0.025-2.0 μg/mL, for all of the protease inhibitors.

The investigators explained that this validated LC/MS assay method uses a small sample volume with a low CV. Use of a small sample volume is advantageous, especially when TDM used for paediatric patients. They noted: “The ability to minimise the amount of blood extracted, handle small patient samples, and rapidly analyse them will enable TDM and pharmacokinetic studies to be used in the paediatric setting.”

Ref: Lam J, M. Neely JM, Bi L, Louie S et al. LC/MS analysis of protease inhibitors. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006, Lisbon. Abstract 17.

2006-06-10
IB060706-09

©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.